<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31864229</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1669-9106</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>Spec 6/1</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Medicina</Title><ISOAbbreviation>Medicina (B Aires)</ISOAbbreviation></Journal><ArticleTitle>[New progress in the treatment of locally advance pancreatic cancer].</ArticleTitle><Pagination><StartPage>576</StartPage><EndPage>581</EndPage><MedlinePgn>576-581</MedlinePgn></Pagination><Abstract><AbstractText>Locally advanced pancreatic cancer (LAPC) has several definitions, but it is essentially a non-metastatic tumor, in which the initial surgical resection is not considered beneficial due to the extensive vascular involvement and consequent high chance of a nonradical resection. The introduction of chemotherapy with calcium leucovorin, fluorouracil, irinotecan hydrochloride and oxaliplatin (FOLFIRINOX) and gemcitabine-nab (nanoparticle albumin-bound)-paclitaxel (gem-nab) had very important implications for the management of patients with LAPC. After 4 to 6 months of induction chemotherapy, a large proportion of them have stable disease or even tumor regression, allowing to rescue those who initially were not candidates for surgery, with 30-35 months overall survival after surgery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Santiba&#xf1;es</LastName><ForeName>Mart&#xed;n</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Secci&#xf3;n H&#xed;gado-V&#xed;as Biliares-P&#xe1;ncreas, Servicio de Cirug&#xed;a General, Secci&#xf3;n de Trasplante Hep&#xe1;tico, Hospital Italiano de Buenos Aires, Argentina. E-mail: martin.desantibanes@hospitalitaliano.org.ar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez Clari&#xe1;</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Secci&#xf3;n H&#xed;gado-V&#xed;as Biliares-P&#xe1;ncreas, Servicio de Cirug&#xed;a General, Hospital Italiano de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Santiba&#xf1;es</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Secci&#xf3;n H&#xed;gado-V&#xed;as Biliares-P&#xe1;ncreas, Servicio de Cirug&#xed;a General, Secci&#xf3;n de Trasplante Hep&#xe1;tico, Hospital Italiano de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pekolj</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Secci&#xf3;n H&#xed;gado-V&#xed;as Biliares-P&#xe1;ncreas, Servicio de Cirug&#xed;a General, Secci&#xf3;n de Trasplante Hep&#xe1;tico, Hospital Italiano de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazza</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Secci&#xf3;n H&#xed;gado-V&#xed;as Biliares-P&#xe1;ncreas, Servicio de Cirug&#xed;a General, Hospital Italiano de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Nuevos avances en el tratamiento del c&#xe1;ncer de p&#xe1;ncreas localmente avanzado.</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Medicina (B Aires)</MedlineTA><NlmUniqueID>0204271</NlmUniqueID><ISSNLinking>0025-7680</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000627770">folfirinox</NameOfSubstance></Chemical><Chemical><RegistryNumber>04ZR38536J</RegistryNumber><NameOfSubstance UI="D000077150">Oxaliplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0W860991D6</RegistryNumber><NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>7673326042</RegistryNumber><NameOfSubstance UI="D000077146">Irinotecan</NameOfSubstance></Chemical><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q573I9DVLP</RegistryNumber><NameOfSubstance UI="D002955">Leucovorin</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000093542">Gemcitabine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003841" MajorTopicYN="N">Deoxycytidine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060828" MajorTopicYN="N">Induction Chemotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077146" MajorTopicYN="N">Irinotecan</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002955" MajorTopicYN="N">Leucovorin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077150" MajorTopicYN="N">Oxaliplatin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093542" MajorTopicYN="N">Gemcitabine</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>El c&#xe1;ncer de p&#xe1;ncreas localmente avanzado (CPLA) tiene varias definiciones, pero esencialmente es un tumor no metast&#xe1;sico, en el que la resecci&#xf3;n quir&#xfa;rgica inicial no se considera beneficiosa debido a la extensa afectaci&#xf3;n vascular y la alta probabilidad de tener m&#xe1;rgenes quir&#xfa;rgicos con compromiso tumoral. La introducci&#xf3;n de la quimioterapia con leucovorina c&#xe1;lcica, fluorouracilo, clorhidrato de irinotec&#xe1;n y oxaliplatino (FOLFIRINOX) y gemcitabina-nab-paclitaxel (paclitaxel acoplado a alb&#xfa;mina, lo que aumenta su solubilidad) ha tenido alcances muy importantes en el tratamiento de pacientes con CPLA. Despu&#xe9;s de 4 a 6 meses de quimioterapia de inducci&#xf3;n, una gran proporci&#xf3;n tiene enfermedad estable o incluso regresi&#xf3;n tumoral, permitiendo rescatarlos quir&#xfa;rgicamente, que de inicio no eran candidatos a una cirug&#xed;a resectiva, con una supervivencia global de 30 a 35 meses.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FOLFIRINOX</Keyword><Keyword MajorTopicYN="N">locally advance pancreatic cancer</Keyword><Keyword MajorTopicYN="N">neoadjuvant chemotherapy</Keyword><Keyword MajorTopicYN="N">radiotherapy</Keyword><Keyword MajorTopicYN="N">surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31864229</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>